Aspen Aerogels Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Aspen Aerogels ont diminué à un taux annuel moyen de -49.6%, tandis que le secteur Chemicals a vu ses bénéfices augmenter de en à 3.7% par an. Les revenus ont augmenté de en à un taux moyen de 29.4% par an.
Informations clés
-49.65%
Taux de croissance des bénéfices
-23.03%
Taux de croissance du BPA
| Chemicals Croissance de l'industrie | 12.93% |
| Taux de croissance des recettes | 29.44% |
| Rendement des fonds propres | -165.40% |
| Marge nette | -143.69% |
| Prochaine mise à jour des résultats | 07 May 2026 |
Mises à jour récentes des performances passées
Recent updates
ASPN: GM Demand Reset And Tough Outlook Will Pressure Shares
Analysts have cut their average price targets on Aspen Aerogels to a range of about $3 to $6. This reflects weaker near term expectations tied to GM related EV softness, offset by company efforts to protect cash, reduce costs, and focus on longer term platform value.
ASPN: Cost Discipline And GM Settlement Cash Will Support Future Upside
Analysts have reduced their average price targets on Aspen Aerogels to a range of about $3 to $6, citing Q4 earnings and guidance shortfalls, ongoing softness tied to GM and the broader EV reset, as well as a sharper company focus on cash preservation and cost controls. Analyst Commentary Across recent research notes, analysts broadly cut price targets on Aspen Aerogels following Q4 results and softer guidance, but the tone is mixed rather than uniformly negative.ASPN: Cost Actions And Cash Support Will Drive Long-Term Upside Potential
Analysts have reduced the fair value estimate for Aspen Aerogels from $10 to $6, reflecting lower price targets across the Street as they weigh weaker GM related EV demand against the company's cost actions, cash support from the GM settlement, and longer term platform potential. Analyst Commentary Street research has shifted sharply lower on headline price targets, but the tone is not uniformly negative.ASPN: Tough Year And GM Demand Reset Will Pressure Shares
Narrative Update: Aspen Aerogels The analyst price target for Aspen Aerogels has moved from $6.00 to $3.00 as analysts factor in a tough year following a Q4 earnings miss and softer guidance, partly offset by cost actions and a stronger net cash position tied to the GM settlement. Analyst Commentary Bearish analysts have reset expectations for Aspen Aerogels, cutting price targets across the board after the Q4 earnings miss and softer near term guidance.Aspen Aerogels: A Long Road Ahead
Feb 27ASPN: Updated Profitability Assumptions Will Still Support Long-Term Upside Potential
Analysts have lifted their price target for Aspen Aerogels to $10.00, citing updated inputs around revenue growth, profit margins, and future P/E assumptions as the key drivers of this change. Valuation Changes Fair Value: revised slightly from $9.98 to $10.00 per share, aligning with the updated price target.
ASPN: Higher 2025 Loss Guidance Will Still Support Long-Term Opportunity
Analysts have adjusted their price target on Aspen Aerogels, highlighting a slightly higher discount rate and future P/E assumptions, along with modest tweaks to revenue growth and profit margin expectations, as they reassess the risk and earnings profile embedded in their valuation models. What's in the News Aspen Aerogels revised full year 2025 revenue guidance to a range of $270 million to $280 million, compared with prior guidance of $297 million to $317 million (company guidance).Aspen Aerogels, Inc.'s (NYSE:ASPN) 32% Share Price Surge Not Quite Adding Up
Jan 23
ASPN: Lower 2025 Guidance Will Still Support Long-Term Upside Potential
Analysts have raised their price targets on Aspen Aerogels, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that together suggest a modest improvement in their overall outlook for the shares. What's in the News Aspen Aerogels revised its full-year 2025 revenue guidance to a range of US$270 million to US$280 million, compared with prior guidance of US$297 million to US$317 million (company guidance).ASPN: Lower 2025 Outlook Will Still Support Attractive Long-Term Upside Potential
Analysts have lifted their price target on Aspen Aerogels to reflect updated assumptions around revenue growth, profit margins, discount rate and future P/E. The new target implies a valuation aligned with these revised inputs compared with the prior figure.ASPN: Reduced Guidance And Higher Discount Rate Will Present Long-Term Upside Opportunity
Aspen Aerogels' consensus analyst price target has been reduced by approximately $4.02 per share, as analysts temper their assumptions for revenue growth and profit margins, while also applying a slightly higher discount rate and multiple to future earnings. What's in the News Aspen Aerogels lowered its full year 2025 revenue guidance to a range of $270 million to $280 million, down from prior expectations of $297 million to $317 million (Key Developments).ASPN: Improving Risk Profile Will Support Long-Term Opportunity Despite Wider Losses
Analysts have raised their price target on Aspen Aerogels by a modest amount, now embedding slightly lower discount rates and marginally softer future valuation multiples, as they emphasize the company’s improving risk profile and steady long term growth outlook. What's in the News Aspen Aerogels lowered its full year 2025 revenue guidance to a range of $270 million to $280 million, down from the prior outlook of $297 million to $317 million (company guidance).Aspen Aerogels (NYSE:ASPN) Might Have The Makings Of A Multi-Bagger
Dec 04ASPN: Lower Profit Margins Will Drive Opportunity As Net Losses Peak
Analysts have lowered their price target for Aspen Aerogels from $8.75 to $6.83 per share. They cite revised expectations for slower revenue growth and profit margins.ASPN: Reduced EV Tax Credits Will Challenge Thermal Segment Performance Ahead
Analysts have lowered their price target for Aspen Aerogels from $9.58 to $8.75. They cited reduced electric vehicle production forecasts and increased macroeconomic pressures on the company’s key Thermal Barrier business segment.Optimistic Investors Push Aspen Aerogels, Inc. (NYSE:ASPN) Shares Up 27% But Growth Is Lacking
Oct 11Aspen Aerogels, Inc. (NYSE:ASPN) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 09Cost Optimization And Industrial Demand Will Shape Future Markets
The consensus price target for Aspen Aerogels has increased, reflecting a higher valuation multiple (future P/E rising from 14.46x to 20.08x) despite a notable decline in net profit margin (from 14.47% to 11.75%), resulting in a new fair value estimate of $9.75. What's in the News Ricardo Rodriguez will step down as CFO at the end of Q3 and be succeeded by Grant Thoele, who currently serves as Chief of Staff and VP of Corporate Strategy and Finance.Aspen Aerogels, Inc.'s (NYSE:ASPN) Shares Climb 28% But Its Business Is Yet to Catch Up
Aug 06Is Aspen Aerogels (NYSE:ASPN) A Risky Investment?
Jul 09Aspen Aerogels, Inc.'s (NYSE:ASPN) 29% Share Price Surge Not Quite Adding Up
Jun 11Not Many Are Piling Into Aspen Aerogels, Inc. (NYSE:ASPN) Stock Yet As It Plummets 30%
Apr 17Aspen Aerogels (NYSE:ASPN) Has A Pretty Healthy Balance Sheet
Apr 01Aspen Aerogels: Tariffs, Tesla And The Silver Lining
Mar 31Positive Sentiment Still Eludes Aspen Aerogels, Inc. (NYSE:ASPN) Following 34% Share Price Slump
Feb 28Aspen Aerogels: Insulation Play Leaves Investors In The Cold
Feb 14Aspen Aerogels (NYSE:ASPN) Is Looking To Continue Growing Its Returns On Capital
Feb 14Aspen Aerogels: There Are Reasons To Be Careful But It's So Cheap
Dec 23Aspen Aerogels: Thermal Barriers Could Sustain Further Growth Despite A Chilly Market
Dec 02Aspen Aerogels: Despite Recent Pressure, This Is Intriguing
Nov 17With A 32% Price Drop For Aspen Aerogels, Inc. (NYSE:ASPN) You'll Still Get What You Pay For
Nov 07Aspen Aerogels: Interesting Times
Oct 28Aspen Aerogels (NYSE:ASPN) Is Looking To Continue Growing Its Returns On Capital
Oct 17Aspen Aerogels: Current Valuation Is Not A Good Risk/Reward
Sep 26Aspen Aerogels: Management Guidance Remains Very Conservative
Sep 18
Decisive Expansion And EV Innovations Propel Aerogel Giant Towards Financial Triumph
Expansion of production capacity and strategic financial management shows promise for significant revenue growth and improved net income through cost efficiency.Why Investors Shouldn't Be Surprised By Aspen Aerogels, Inc.'s (NYSE:ASPN) 32% Share Price Surge
Aug 24Investors Shouldn't Be Too Comfortable With Aspen Aerogels' (NYSE:ASPN) Earnings
Aug 15Aspen Aerogels: Impressive, But Some Questions As Well
Aug 12Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Aspen Aerogels gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 25 | 271 | -390 | 84 | 13 |
| 30 Sep 25 | 353 | -305 | 89 | 15 |
| 30 Jun 25 | 397 | -312 | 96 | 17 |
| 31 Mar 25 | 437 | -286 | 103 | 18 |
| 31 Dec 24 | 453 | 13 | 107 | 18 |
| 30 Sep 24 | 414 | 1 | 104 | 18 |
| 30 Jun 24 | 357 | 1 | 101 | 17 |
| 31 Mar 24 | 288 | -31 | 95 | 17 |
| 31 Dec 23 | 239 | -46 | 90 | 16 |
| 30 Sep 23 | 214 | -55 | 85 | 16 |
| 30 Jun 23 | 190 | -71 | 78 | 17 |
| 31 Mar 23 | 188 | -80 | 74 | 17 |
| 31 Dec 22 | 180 | -83 | 67 | 17 |
| 30 Sep 22 | 152 | -89 | 59 | 16 |
| 30 Jun 22 | 146 | -68 | 53 | 14 |
| 31 Mar 22 | 132 | -50 | 45 | 13 |
| 31 Dec 21 | 122 | -37 | 39 | 11 |
| 30 Sep 21 | 113 | -27 | 35 | 10 |
| 30 Jun 21 | 107 | -26 | 30 | 9 |
| 31 Mar 21 | 100 | -25 | 28 | 9 |
| 31 Dec 20 | 100 | -22 | 27 | 9 |
| 30 Sep 20 | 124 | -17 | 29 | 9 |
| 30 Jun 20 | 135 | -12 | 31 | 9 |
| 31 Mar 20 | 140 | -12 | 31 | 9 |
| 31 Dec 19 | 139 | -15 | 32 | 8 |
| 30 Sep 19 | 129 | -28 | 33 | 8 |
| 30 Jun 19 | 117 | -32 | 32 | 7 |
| 31 Mar 19 | 109 | -34 | 33 | 7 |
| 31 Dec 18 | 104 | -34 | 33 | 6 |
| 30 Sep 18 | 105 | -22 | 30 | 6 |
| 30 Jun 18 | 108 | -19 | 30 | 6 |
| 31 Mar 18 | 112 | -17 | 30 | 6 |
| 31 Dec 17 | 112 | -19 | 32 | 6 |
| 30 Sep 17 | 103 | -23 | 32 | 6 |
| 30 Jun 17 | 105 | -23 | 33 | 6 |
| 31 Mar 17 | 108 | -19 | 32 | 6 |
| 31 Dec 16 | 118 | -12 | 29 | 5 |
| 30 Sep 16 | 127 | -5 | 28 | 5 |
| 30 Jun 16 | 129 | -4 | 27 | 5 |
| 31 Mar 16 | 132 | -5 | 27 | 5 |
| 31 Dec 15 | 123 | -6 | 26 | 5 |
| 30 Sep 15 | 113 | -11 | 25 | 6 |
| 30 Jun 15 | 107 | -11 | 25 | 6 |
Des revenus de qualité: ASPN n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: ASPN n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ASPN n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 49.6% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de ASPN au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: ASPN n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Chemicals ( 0.1% ).
Rendement des fonds propres
ROE élevé: ASPN a un retour sur capitaux propres négatif ( -165.4% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/04/30 23:56 |
| Cours de l'action en fin de journée | 2026/04/30 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Aspen Aerogels, Inc. est couverte par 16 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Benjamin Kallo | Baird |
| J. David Anderson | Barclays |
| J. David Anderson | Barclays |